Eli Lilly gets FDA approval for new migraine drug

Friday, September 28, 2018 9:51 AM | Michael Fowlkes

Morning News Leader

Eli Lilly and Company (LLY) is up 0.1% Friday morning. The company announced the U.S. Food and Drug Administration approved its new migraine drug Emgality. The drug is expected to sell for $575 a month, in-line with two other new drugs that are on the market.

Eli Lilly and Company (LLY) is a drug manufacturer.

Lowe's Companies, Inc. (LOW) and The Boeing Company (BA) top the list of other companies with positive news today, while Tesla, Inc. (TSLA) and Applied Optoelectronics, Inc. (AAOI) top the list of companies with negative news.

Share this article:

Related Companies

Trade Options Like a Pro with Elite Options

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 73% with annual

InvestorsObserver Elite Options

$ 37.42 $ 18.71 /month
$449 $224.50 billed annually

You May Also Like

Related Companies